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ABSTRACT
This study investigated the effect of copy number and transcriptional level of the qnrA gene on plasmid-
mediated quinolone resistance, and the effect of quinolones on qnrA expression, in three clinical isolates
of Klebsiella pneumoniae and the corresponding Escherichia coli transconjugants. The copy number of
plasmids containing qnrA was analysed and transcriptional studies were performed on transconjugants
grown in the presence or absence of ciproﬂoxacin or moxiﬂoxacin. None of the three clinical isolates was
porin-deﬁcient. One isolate contained a mutation in the quinolone resistance-determining region of the
gyrA gene (Ser83Phe), but no gyrA mutations were present in the other two isolates, and no mutations
were found in parC. Differences in qnrA copy number were observed in K. pneumoniae, but not in the
corresponding E. coli transconjugants, although the qnrA gene was located in plasmids with similar
mobility and Southern blot RFLP pattern. Differences in qnrA transcription, both at the basal level and
following induction by quinolones, were observed among transconjugants. Expression of the qnrA gene
correlated well with the level of quinolone (ciproﬂoxacin and moxiﬂoxacin) resistance in E. coli
transconjugants. These data suggest that the main factor determining the resistance level in the
transconjugants analysed was the different levels of qnrA expression.
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INTRODUCTION
Quinolone resistance in Gram-negative bacteria
is usually caused by mutations in the chromo-
somal genes coding for type II topoisomerases,
the target of quinolone action [1], and changes
in the expression of efﬂux pumps and porins,
causing decreased accumulation of these agents
inside the bacterial cell [2]. However, plasmid-
mediated resistance, mediated by the qnrA gene
[3] and other related genes, has also been
described.
The qnrA gene has been located on plasmids,
ranging from 54 to 180 kb in size, in clinical
isolates of Klebsiella pneumoniae, Escherichia coli,
Providencia stuartii, Citrobacter freundii and Ente-
robacter spp. The qnrA gene confers low-level
quinolone resistance when transferred by con-
jugation to a sensitive recipient strain [3–5], and
encodes a protein with 218 amino-acids that
belongs to the pentapeptide repeat family. Puri-
ﬁed QnrA protects DNA gyrase and topoiso-
merase IV activities in vitro by reducing the
number of holoenzyme-DNA targets for quino-
lone inhibition [6,7]. Plasmids containing qnrA
can also encode the AmpC-type b-lactamase
FOX-5, the extended-spectrum b-lactamases
(ESBLs) SHV-7, CTX-M-9 and VEB1, and the
narrow-spectrum enzyme PSE-1 [5,8–10]. This
observation may explain, in part, the genetic
linkage between resistance to b-lactams and
quinolones in ESBL-producing isolates, in which
quinolone resistance is found with high fre-
quency [11].
The qnrA gene has been found within sul1-type
integrons of the In4 family complex [5]. Integrons
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of this type contain duplicated qacED1 and sul1,
which, in most cases, surround orf513, presumed
to encode a recombinase that mobilises genes
(such as qnrA). The qnrA gene lacks the 59-bp
element usually associated with resistance genes
found in integrons [12]. However, beyond these
structural details, little is known about the regu-
lation of qnrA expression.
Some antimicrobial agents are able to regulate
the expression of genes that are directly or
indirectly related to resistance. It is well-known
that the expression of both chromosomal and
some plasmid-encoded AmpC b-lactamases is
induced by b-lactams [13]. In Staphylococcus aure-
us, ciproﬂoxacin induces the expression of genes
related to oxidative stress, while vancomycin and
oxacillin induce transcription of the pbpB struc-
tural gene [14]. Norﬂoxacin induces an SOS
response, as well as other genes of unknown
function, in E. coli [15].
In this report, three clonally unrelated K.
pneumoniae clinical isolates carrying qnrA, and
their derived E. coli transconjugants, were inves-
tigated. Different MICs were observed for trans-
conjugants obtained from different donor isolates
[4]. The relationship between genetic environ-
ment, copy number and basal transcription level
of qnrA was analysed in relation to differences in
the ﬂuoroquinolone MICs for the transconjugants.
In addition, the effect of two ﬂuoroquinolones
(ciproﬂoxacin and moxiﬂoxacin) on qnrA expres-
sion was evaluated.
METHODS AND MATERIALS
Bacterial strains, growth conditions and susceptibility tests
Three clinical K. pneumoniae isolates from the USA, UAB1 [3],
N5 and 1960 [4], which carried qnrA, were investigated. All
three isolates expressed porins in their respective outer-
membranes. The corresponding transconjugants (TC) in E. coli
J53AzR (met, pro, azir) [3,4] were also analysed. All bacteria
were grown routinely at 37C in Luria-Bertani broth (LB) or on
Mueller-Hinton agar plates (MHA). The CLSI (formerly
NCCLS) microdilution broth method was used to determine
antimicrobial susceptibility [16].
Plasmid analysis and characterisation of gyrA and parC
In brief, plasmid DNA from the clinical isolates and transcon-
jugants was obtained using the UltraClean Mini Plasmid Prep
kit (Mo Bio Laboratories, Inc., Solana Beach, CA, USA),
according to the manufacturer’s protocol. Quinolone resist-
ance-determining regions of the gyrA and parC genes were
ampliﬁed by PCR and sequenced with primers gyrA-F
(5¢-AAATCTGCCCGTGTCGTTGGT), gyrA-R (5¢-GCCATAC-
CTACGGCGATACC), parC-F (5¢-CTGAATGCCAGCGC-
CAAATT) and parC-R (5¢-GCGAACGATTTCGGATCGTC)
(V. J. Benedi, personal communication).
b-Lactamase characterisation
The presence of the blafox-5 gene was investigated by PCR with
primers FOX-F (5¢-ATGTGGACGCCTTGAACT) and FOX-R
(5¢-CACCACGAGAATAACCAT), followed by sequencing
with the same primers [17].
Dot-blot and Southern blot analysis
In brief, plasmid DNA from donors and transconjugants was
extracted from 4-mL cultures grown in LB medium containing
ampicillin 100 mg ⁄L. The cells were harvested and plasmid
DNA was extracted and analysed by dot-blot or Southern blot
restriction fragment length polymorphism (RFLP). DNA was
quantiﬁed in a GeneQuant Pro Spectrophotometer (Amersham
Bioscience, Little Chalfont, UK). EcoRI was used to digest
plasmid DNA for Southern blot RFLP analysis. Dot-blots and
Southern blots were performed using standard protocols [18].
The probe used to detect the qnrA gene was a 543-bp PCR
fragment ampliﬁed from plasmid DNA pMG252 with primers
qnrA-F (5¢-ATCCAGATCGGCAAAGGTTA) and qnrA-R (5¢-
GATAAAGTTTTTCAGCAAGAGG) as described previously
[4]. The qnrAprobewas labelledusing theDIGHighPrimeDNA
Labelling kit (Roche, Sant Cugat del Valle´s, Spain) according to
themanufacturer’s instructions. Serial dilutions (300 ng, 150 ng,
75 ng and 37.5 ng) of plasmid DNA were spotted on to the
membranes.DNAwasﬁxedbyUVcross-linking.Quantiﬁcation
of relative copy numbers was performed using 1D Image
Analysis software (Kodak, Rochester, NY, USA). The assay was
repeated in at least three different experiments.
Northern blotting
In brief, bacterial cultures were grown at 37C in LB
containing ampicillin 100 mg ⁄L to ensure plasmid mainten-
ance. Cells were collected during the exponential phase and
RNA was isolated using the High Pure RNA Isolation kit
(Roche). Lysis of cells was facilitated with lysozyme (Amer-
sham Bioscience). RNA purity was determined on the basis
of the A260 ⁄A280 ratio. RNA (10 lg) was denatured with
glyoxal and dimethylsulphoxide [18] for 1 h at 55C, and
was then electrophoresed through agarose 1.2% w ⁄v gels in
running buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.1).
rRNA was also used as a load control in quantiﬁcation
experiments. Equivalent amounts of RNA were loaded per
lane. rRNA bands were visualised by methylene blue
staining of the membrane after transfer as described previ-
ously [18], and were used as a reference to estimate the size
of the qnrA transcript. 10 · SSC (1 · SSC is 0.15 M NaCl,
0.015 M sodium citrate) was used as the transfer buffer.
RNA was transferred on to a Hybond-N+ membrane
(Amersham Bioscience) and was ﬁxed by UV cross-linking.
The qnrA probe was the same fragment as described above
for Southern blot assays. Hybridisation was performed
under conditions of high stringency and membranes were
exposed to Hyperﬁlm-ECL (Roche). Quantiﬁcation of relative
transcript numbers was performed using 1D Image Analysis
software. The assay was repeated in at least three inde-
pendent experiments.
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To evaluate the effect of ciproﬂoxacin and moxiﬂoxacin on
qnrA expression in the transconjugants, cells were grown for
different periods (30 min, 1 h, 2 h, 4 h, 6 h and 8 h) from an
exponential culture in the presence of either ciproﬂoxacin or
moxaﬂoxacin at 0.2, 0.4, 0.8 or 1· the respective MICs. In
preliminary experiments, the levels of expression of qnrA did
not vary with the exposure time. Following these preliminary
experiments, the comparative effects of ciproﬂoxacin and
moxiﬂoxacin on qnrA expression were tested at 0.4 · MIC for
4 h. In the latter two assays, a parallel control of cells grown in
the absence of quinolones was also evaluated. The blafox5 gene
was used as an internal control in the expression assays.
RESULTS AND DISCUSSION
Transconjugants obtained from the same donor
had similar ﬂuoroquinolone MICs, while different
MICs were observed for transconjugants obtained
from different donors. MICs ranged from
0.125 mg ⁄L (in N5 TC and 1960 TC) to 0.5 mg ⁄L
(in UAB1 TC) for ciproﬂoxacin, and from
0.125 mg ⁄L (in N5 TC and 1960 TC) to
0.25 mg ⁄L (in UAB1 TC) for moxiﬂoxacin
(Table 1) [4]. In order to ensure that these differ-
ences were not caused by intrinsic one-dilution
step variations, susceptibility testing was per-
formed in triplicate, on three different days. In all
cases, the results obtained conﬁrmed the differ-
ence in ﬂuoroquinolone MICs for the different
transconjugants.
Isolates N5 and 1960 carried a qnrA gene with a
nucleotide sequence identical to that reported
originally for plasmid pMG252 in isolate UAB1
[6]. EcoRI-digested plasmid DNA from the three
isolates and their corresponding transconjugants
was analysed by Southern blot RFLP and showed a
similar positive fragment of c. 4. kb following
hybridisation with the qnrA probe (Fig. 1). These
results suggest that qnrA might be located in a
genetic environment similar to that of the original
qnrA plasmid, pMG252 [6]. The qnrA plasmids
from isolates N5 and 1960 also had the same
mobility as pMG252 (estimated size, c. 160 kb)
(data not shown). All three plasmids carried the
blafox-5 gene. Similar patterns of resistance were
observed for the transconjugants carrying qnrA
with all antimicrobial agents tested except rifampi-
cin; the transconjugant derived from UAB1 was
Table 1. Properties and resistance proﬁles of clinical isolates of Klebsiella pneumoniae and the Escherichia coli transcon-
jugants [4]
Species
MIC
(mg ⁄L)
pDNA
foldsa
Transcript
qnrA
basal
foldsb
Increase in
transcript qnrA
foldsc
GyrA
change PorinsCIP MFX CIP MFX
Donors
UAB1 K. pneumoniae 2 1 8.9 ± 1.0 None +
N5 K. pneumoniae 0.25 0.5 4.3 ± 1.0 None +
1960 K. pneumoniae 1 1 1 S83F +
Transconjugants
UAB1 TC E. coli 0.5 0.25 1 4.04 ± 0.7 4.3 ± 0.5 4.1 ± 0.3 None
N5 TC E. coli 0.125 0.125 1.8 ± 0.3 1.2 ± 0.2 5.1 ± 0.2 2.3 ± 0.3 None
1960 TC E. coli 0.125 0.125 1.3 ± 0.1 1 2.6 ± 0.4 1.3 ± 0.1 None
Recipient J53AzR E. coli 0.008 0.008
apDNA folds (expressed as median ± SD) indicate the relative copy numbers of qnrA with respect to the lowest value obtained, which is considered as 1. Copy numbers were
determined separately for K. pneumoniae donors and E. coli transconjugants (TC).
bTranscript qnrA basal folds (expressed as median ± SD) indicate the relative numbers of qnrA transcripts with respect to the lowest value obtained, which is considered as 1.
cIncrease in transcript qnrA folds indicates the increase in the number of qnrA transcripts with respect to the value obtained for non-quinolone-exposed cells.
CIP, ciproﬂoxacin; MFX, moxiﬂoxacin.
1 2 3 4 5 6 7 8 9
23 kb
9.4 kb
6.5 kb
4.3 kb
2.3 kb
2.0 kb
Fig. 1. Southern hybridisation of plasmid DNA digested
with EcoRI and probed with qnrA. Lanes: 1 and 9, k-HindIII
DNA size marker; 2, negative control Escherichia coli
J53AzR; 3, 5 and 7, clinical isolates UAB1, N5, 1960; 4, 6
and 8 correspond to UAB1, N5 and 1960-derived trans-
conjugants.
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susceptible to rifampicin, unlike the N5 and 1960
transconjugants. Overall, these data show that the
three plasmids have similar characteristics, despite
being present in isolates obtained from different
geographical locations [3,4].
K. pneumoniae UAB1 and N5 contained eight-
fold and three-fold more qnrA copies, respect-
ively, than K. pneumoniae 1960 (Table 1; Fig. 2).
However, it was difﬁcult to correlate the copy
number and level of resistance precisely as other
mechanisms of resistance were also present in
these clinical isolates. Porin proﬁles were inves-
tigated by SDS-PAGE. None of the three clinical
isolates appeared to be porin-deﬁcient. K. pneumo-
niae 1960 contained a mutation in the quinolone
resistance-determining region of GyrA
(Ser83Phe), but no gyrA mutations were detected
in the other two isolates, and no mutations were
found in parC (Table 1). The presence of efﬂux
pumps or other novel quinolone resistance genes
might explain the different MICs for the clinical
isolates and their transconjugants [19,20]. Minor
differences in qnrA copy number were observed
among the transconjugants (Table 1; Fig. 2). As
E. coli J53AzR was the recipient in all cases,
differences in plasmid DNA replication associ-
ated with different host strains can be ruled out.
Thus, these results suggest that copy number is
not the critical factor for determining the level of
resistance.
To determine whether the different MICs
observed for transconjugants derived from differ-
ent donors were caused by differential transcrip-
tion of the qnrA gene, the number of qnrA-speciﬁc
transcripts was compared by northern blotting.
As shown in Fig. 3(A), the number of qnrA
transcripts was c. four-fold greater in the trans-
conjugant derived from UAB1 than for the trans-
conjugants derived from N5 or 1960. The qnrA
probe detected a transcript of c. 0.8 kb (as esti-
mated by comparison with 16S and 23S rRNA).
The higher basal expression of qnrA in the UAB1
transconjugant may explain, at least in part, the
higher MICs of quinolones for this transconjugant
[4]. Variations in promoter structure may explain
these differences [10].
A dose–response study of the effect of cipro-
ﬂoxacin on qnrA transcription was performed
with transconjugants from strains UAB1, N5 and
1960. The abundance of qnrA transcript in the
UAB1 transconjugant was greater than in trans-
conjugants derived from N5 and 1960 (Fig. 3B), in
line with the higher level of basal expression in
UAB1. As seen in the northern blots with the qnrA
probe (Fig. 3B), qnrA transcript levels increased in
all three isolates when ciproﬂoxacin was present
in the medium at 0.4 · MIC, with 4.3-fold, 5.1-
fold and 2.6-fold increases for UAB1, N5 and
1960, respectively.
1
300 ng
150 ng
75 ng
37.5 ng
pDNA
2 3 4 5 6 7
Fig. 2. Quantitative determination of the plasmid copy
number of the qnrA gene. Dot-blot analysis was performed
following serial dilution (300 ng, 150 ng, 75 ng and
37.5 ng) of plasmid DNA (pDNA). Lanes: 1, 2 and 3,
UAB1, N5 and 1960-derived transconjugants; 4, negative
control Escherichia coli J53AzR; 5, 6 and 7, clinical isolates
UAB1, N5 and 1960.
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Fig. 3. Comparative analysis of the increase of qnrA
expression in the presence of ciproﬂoxacin (CIP) and
moxiﬂoxacin (MXF). (A) Basal expression of the qnrA gene
in the three different transconjugants. (B) qnrA transcrip-
tion in the presence of CIP and MXF at 0.4 · MIC for 4 h in
transconjugants (TC) derived from UAB1, N5 and 1960
isolates. NI, cells cultured in the absence of antibiotics.
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Since qnrA can confer resistance to other quino-
lones, the effect of moxiﬂoxacin was also inves-
tigated. Given that the MICs of ciproﬂoxacin and
moxiﬂoxacin are different (Table 1), several con-
centrations of these antimicrobial agents were
tested. Maximal transcription occurred at c.
0.4 · MIC with both ciproﬂoxacin and moxiﬂoxa-
cin (data not shown). The increases over baseline
observed when moxiﬂoxacin was added to the
medium at 0.4 · MIC were 4.1-fold, 2.3-fold and
1.3-fold for the transconjugants derived from
UAB1, N5 and 1960, respectively.
The internal control, blafox5, showed the same
level of expression in the presence and absence of
quinolones (data not shown). Although non-spe-
ciﬁc changes in relative mRNA expression could
occur throughprolonged incubation at toxic quino-
lone levels, the rRNA load control and the blafox5
internal control showed that the change in expres-
sion was speciﬁc to the qnrA gene. An increase in
qnrA expression in the presence of ciproﬂoxacin or
moxiﬂoxacin makes sense for bacterial survival. A
higher number of qnrA transcripts could provide
the cell with a rapid response to the damaging
effects of antimicrobial agents that inhibit DNA
replication by protecting the topoisomerases.
In conclusion, both the basal and induced
levels of qnrA transcription correlated well with
the MICs of ciproﬂoxacin and moxiﬂoxacin. It can
therefore be proposed that the main factor inﬂu-
encing resistance in the transconjugants analysed
was the level of qnrA expression, especially since,
in this case, higher plasmid copy numbers did
not correspond to higher levels of resistance.
Further investigations are required to determine
whether qnrA is expressed from the same pro-
moter on all three plasmids, and how this might
affect expression. Recently, two novel quinolone
resistance genes related to the qnrA gene, namely
qnrS and qnrB, have also been described on
transferable plasmids [19,20]. Whether other
plasmid factors affect the expression of qnrA, or
whether other plasmid-encoded genes contribute
to the differences in quinolone resistance, re-
mains to be determined.
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